O13. Subtype-specific KRAS mutations in advanced lung adenocarcinoma

BACKGROUND: So far there is no strong evidence for the predictive effects of KRAS mutations on the clinical outcome of platinum-based chemotherapy in advanced lung adenocarcinoma. However, most of the studies did not take into account the subtype-specific mutations in the KRAS gene. METHODS: For thi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transl Lung Cancer Res
Prif Awduron: Lohinai, Zoltan, Cserepes, Mihaly, Ostoros, Gyula, Moldvay, Judit, Ghanim, Bahil, Laszlo, Viktoria, Hoda, Mir Alireza, Klepetko, Walter, Hegedus, Balazs, Dome, Balazs
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Pioneer Bioscience Publishing Company 2014
Pynciau:
CELCC 2014 Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367747/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB012
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg